Celgene

Jump to

Revlimid drug: Biocon enters patent litigation settlement with Celgene

Celgene Corporation earlier filed a complaint against Biocon over potential patent infringement by a potential generic drug created by Biocon.
Drugmaker Bristol-Myers to buy Celgene for $74 billion

Celgene shareholders will receive one Bristol-Myers Squibb share and $50 in cash for each share held, or $102.43 per share, a premium of 53.7 percent to Celgene's closing on January 2.
Biosimilars to lead growth; generics to be a small part: Biocon

Biotechnology major Biocon reported 19.8 percent rise in revenue to Rs 796.2 crore year-on-year and margins grew to 25.2 percent from 21.2 percent in the second quarter of FY17. The company‘s standalones sale grew 17 percent in Q2.
Glenmark, Particle Sciences to develop generic cancer drug

Glenmark Pharmaceuticals today said it has entered into an agreement with US-based Particle Sciences Inc to develop and market a generic version of Celgene's ABRAXANE which is used in treatments of breast and lung cancers.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347

Celgene

Revlimid drug: Biocon enters patent litigation settlement with Celgene

Drugmaker Bristol-Myers to buy Celgene for $74 billion

Biosimilars to lead growth; generics to be a small part: Biocon

Glenmark, Particle Sciences to develop generic cancer drug